Could a gut bacteria byproduct tame MS?
NCT ID NCT07318129
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a daily supplement of indole-3-propionic acid (IPA), a substance naturally made by gut bacteria, can help people with relapsing-remitting multiple sclerosis (RRMS). Over 27 months, 220 adults will take either IPA or a placebo. The main goal is to see if IPA reduces disease activity, including relapses, brain lesions, and disability progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Indole-3-propionic acid (IPA), a natural gut bacteria byproduct, taken as a daily supplement
What this could lead to
If it works, this could point toward a simple dietary supplement that helps control MS disease activity and slow neurodegeneration.
What could go wrong
This is an early-stage trial with no phase designation, so results are uncertain. The supplement may not outperform placebo, and benefits may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Glostrup Hospital
RECRUITINGGlostrup Municipality, 2600, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••